Recent progress in the use of glycine transporter-1 inhibitors for the treatment of central and peripheral nervous system diseases

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 2, 2004, Pages 201-214

  Slassi, Abdelmalik ^a   Egle, Ian ^a  

^a Discovery Chemistry Department   (Canada)

Author keywords

CNS; Glycine; Glycine transporter 1(GlyT 1); NMDA; NMDA receptor; Potency; Schizophrenia; Selectivity

Indexed keywords

1 BENZYL 4 [N [2 METHOXYPHENYL] N (4 METHOXYPHENYLSULFONYL)AMINO]PIPERIDINE; 2 [N [3 [4 (BENZOYL)PHENOXY] 3 PHENYLPROPYL] N METHYLAMINO]ACETIC ACID; 2 [N METHYL 3 PHENYL 3 [4 (4 METHYLPHENOXY)PHENOXY]PROPYLAMINO]ACETIC ACID; 3 [N' [2,6 DINITRO 4 TRIFLUOROMETHYLPHENYL] N (3 METHOXYPHENYL)HYDRAZINO]PROPIONITRILE; 3 AMINO 1 HYDROXY 2 PYRROLIDINONE; 4 [3 ISOPROPYL 5 (6 PHENYLPYRIDIN 3 YL) 4H 1,2,4 TRIAZOL 4 YL] 2,1,3 BENZOXADIAZOLE; 7 CHLOROKYNURENIC ACID; ACETIC ACID DERIVATIVE; ALX 2082; ALX 5407; AMINO ACID DERIVATIVE; AMINO ACID TRANSPORTER; CLOZAPINE; CYCLOSERINE; CYSTEINE DERIVATIVE; DEXTRO SERINE; GLYCINE; HALOPERIDOL; HYDRAZINE DERIVATIVE; KETAMINE; N [3 [4' FLUOROPHENYL] 3 (4' PHENYLPHENOXY)PROPYL]SARCOSINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL N [(4 TRIFLUOROMETHYL)PHENOXY] 3 PHENYLPROPYLGLYCINE; NEUROLEPTIC AGENT; ORG 24461; ORG 24598; PIPERIDINE DERIVATIVE; PROTEIN INHIBITOR; SULFONAMIDE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

BINDING AFFINITY; CLINICAL TRIAL; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; ELECTROENCEPHALOGRAPHY; HUMAN; MEMORY DISORDER; NEUROTRANSMISSION; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SCHIZOPHRENIA; TRANQUILIZING ACTIVITY;

EID: 1242285110     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.2.201     Document Type: Review

References (64)

1. VANDENBERG RJ, AUBREY KR: Glycine transport inhibitors as potential antipsychotic drugs. Expert Opin. Ther. Targets (2001) 5(10):507-518.
2. JAVITT DC: Glycine modulators in schizophrenia. Curr. Opin. Invest. Drugs (2002) 3(7):1067-1072.
3. ARMER RE, MILLER DJ: Advances in potential therapeutic uses of inhibitors of CNS selective amino acid. Expert Opin. Ther. Patents (2001) 11(4):563-572.
4. ARMER RE: Inhibitors of mammalian central nervous system selective amino acid transporters. Curr. Med. Chem. (2000) 7:199-209.
5. ISAAC M, O'BRIEN A, SLASSI A et al.: Synthesis and structure-activity relationship of novel chiral ligands for the glycine-reuptake transporter Type-2 (GlyT-2). Pharmachem. (2003) 2(5):38-43.
6. LÓPEZ-CORCUERA B, MATINEZ-MAZA R, NÚNEZ E et al.: Glycine transporters in the central nervous system. Recent Res. Dev. Neuroch. (2000) 3:161-173.
7. LÓPEZ-CORCUERA B, GERLINGS A, ARAGÓN C: Glycine neurotransmitter transporters: an update. Mol. Membr. Biol. (2001) 18:13-20.
8. GADEA A, LÓPEZ-COLOME AM: Glial transporters for glutamate, glycine, and GABA III. Glycine transporters. Neurosci. Res. (2001) 64:218-222.
9. - neurotransmitter transporters. J. Neurochem. (1998) 71: 1785-1803.
10. GOMEZA J, OHNO K, BETZ H: Glycine transporter isoforms in the mammalian central nervous system: structures, functions and therapeutic promises. Curr. Opin Drug. Discov. Devel. (2003) 6(5):675-682.
11. KANNER BI: Ion-coupled neurotransmitter transport. Curr. Opin. Cell. Biol. (1989) 1(4): 735-738.
12. LAUBE B, MAKSAY G, SCHEMM R et al.: Modulation of glycine receptor function: a novel approach for therapeutic intervention at inhibitory synapses? Trends Pharmacol. Sci. (2002) 23(11):519-527.
13. BETZ: Ligand-gated ion channels in the brain: the amino acid receptor superfamily. Neuron (1990) 5(4):383-392.
14. BERGERON R, MEYER TM, COYLE JT et al.: Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc. Natl. Acad. Sci. USA (1998) 95(26):15730-15735.
15. DANYSZ W, PARSONS CG: Glycine B recognition site of NMDA receptors and its antagonists. Amino Acids (1998) 14(1-3):205-206.
16. 3H]-(N-[3-(4′-fluorophenyl)-3-(4′phenylphenoxy propyl])sarcosine. Neuropharmacology (2003) 45(5):585-593.
17. GUASTELLA J, BRECHA N, WEIGMANN C et al.: Cloning, expression, and localization of a rat brain high-affinity glycine transporter. Proc. Natl. Acad. Sci. USA (1992) 89(15):7189-7193.
18. LIU QR, LÓPEZ-CORCUERA B, MANDIYAN SC et al.: Cloning and expression of a spinal cord and brain-specific glycine transporter with novel structure features. J. Biol. Chem. (1993) 268(30) 22802-2808.
19. PACHOLCZYK T, BLAKELY RD, AMARA SG: Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature (1991) 350(6316):350-354.
20. LIU QR, NELSON H, MANDIYAN S et al.: Cloning and expression of glycine transporter from mouse brain. FEBS Lett. (1992) 305(2):110-114.
21. KIM KH, KINGSMORE SF, HAN H et al.: Cloning of the human glycine transporter Type 1: molecular and pharmacological characterization of novel isoform variants and chromosomal localization of the gene in the human and mouse genomes. Mol. Pharmacol. (1994) 45(4):608-617.
22. GUASTELLA J, NELSON N, NELSON H et al.: Cloning and expression of a rat brain GABA transporter. Science (1990) 249(4974):1303-1306.
23. SMITH KE, BORDEN LA, HARTIG PR et al.: Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron (1992) 8(5):927-935.
24. LÓPEZ-CORCUERA B, LIU QR, MANDIYAN S et al.: Expression of a mouse brain cDNA encoding novel γ-aminobutyric acid transporter. J. Biol. Chem. (1992) 267(25):17491-17493.
25. BOROWSKY B, MEZEY E, HOFFMAN BJ et al.: Two glycine transporter variants with distinct localization in the CNS and peripheral tissues are encoded by a common gene. Neuron (1993) 10(5):851-863.
26. HERDON HJ, GODFREY FM, BROWN AM et al.: Pharmacological assessment of the role of the glycine transporter GlyT-1 in mediating high-affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomes. Neuropharmacology (2001) 41:88-96.
27. PONCE J, POYATOS I, ARAGON C et al.: Characterization of the 5′ region of the rat brain glycine transporter GlyT-2 gene: identification of a novel isoform. Neurosci. Lett. (1998) 242(1):25-28.
28. TSEN G, WILLIAMS B, ALLAIRE P et al.: Receptors with opposing functions are in postsynaptic microdomains under one presynaptic terminal. Nat. Neurosci. (2000) 3(2):126-132.
29. ZAFRA F, GOMEZA J, OLIVARES L et al.: Regional distribution and developmental variation of the glycine transporters GlyT-1 and GlyT-2 in the rat CNS. Eur. J. Neurosci. (1995) 7(6):1342-1352.
30. SUPPLISSON S, BERGMAN C: Control of NMDA receptor activation by a glycine transporter co-expressed in Xenopus oocytes. J. Neurosci. (1997) 17(12):4580-4590.
31. ROUX MJ, SUPPLISSON S: Neuronal and glial glycine transporters have different stoichiometries. Neuron (2000) 25(2):373-383.
32. AUBREY KR, MITROVIC AD, VANDENBERG RJ: Molecular basis for proton regulation of glycine transport by glycine transporter subtype 1b. Mol. Pharmacol. (2000) 58(1):129-135.
33. ATKINSON BN, BELL SC, DE VIVO M et al.: ALX 5407: a potent, selective inhibitor of the hGlyT-1 glycine transporter. Mol. Pharmacol. (2001) 60(6):1414-1420.
34. AUBREY KR, VANDENBERG RJ: N[3-(4′-Fluorophenyl)-3-(4′-phenylphenoxy)propyl]sarcosine (NFPS) is a selective persistent inhibitor of glycine transport. Br. J. Pharmacol. (2001) 134(7):1429-1436.
35. KLECKNER NW, DINGLEDINE R: Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science (1988) 241(4867):835-837.
36. BERGER AJ, DIEUDONNE S, ASCHER P: Glycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses. J. Neurophysiol. (1998) 80(6):3336-3340.
37. KINNEY GG, SUR C, BURNO M et al.: The glycine transporter Type 1 inhibitor N-[3-(4′-fluorophenyl)-3-(4′-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. J. Neurosci. (2003) 23(20):7586-7591.
38. HERESCO-LEVY U, JAVITT DC, ERMILOV M et al.: Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry. (1999) 56(1):29-36.
39. HERESCO-LEVY U: N-Methyl-D-aspartate (NMDA) receptor-based treatment approaches in schizophrenia: the first decade. Int. J. Neuropsychopharmacol. (2000) 3(3):243-258.
40. KRYSTAL JH, D'SOUZA DC, MATHALON D et al.: NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) (2003) 169(1-4):215-233.
41. KRYSTAL JH, KARPER LP, SEIBYL JP et al.: Subanesthetic effects of the non-ompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry. (1994) 51(3):199-214.
42. MALHOTRA AK, PINALS DA, WENGARTNER H et al.: NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology (1996) 14(5):301-307.
43. RADANT AD, BOWDLE TA, COWLEY DS et al.: Does ketamine-mediated N-methyl-D-aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities? Neuropsychopharmacology (1998) 19(5):434-444.
44. KEW NC, KOESTER A, MOREAU JL et al.: Functional consequences of reduction in NMDA receptor glycine affinity in mice carrying targeted point mutations in the glycine binding sites. J. Neurosci. (2000) 20(11):4037-4049.
45. NOWAK G, TRULLAS R, LAYER RT et al.: Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry (1996) 29(1):23-26.
46. JAVITT DC, FRUSCIANTE M: Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: implications for schizophrenia and substance abuse. Psychopharmacology (Berl) (1997) 129(1):96-98.
47. JENTSCH JD, REMOND DE, ELSWORTH JD et al.: Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science (1997) 277(5328):953-955.
48. ARVANOV VL, LIANG X, SCHWARTZ J et al.: Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J. Pharmacol. Exp. Ther. (1997) 283(1):226-234.
49. JAVITT DC: Management of negative symptoms of schizophrenia. Curr. Psychiatry. Rep. (2001) 3(5):413-417.
50. GOFF DC, HENDERSON A, EVINS E et al.: A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol. Psychiatry (1999) 45(4):512-514.
51. GOFF DC, TSAI G, LEVITT J et al.: A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch. Gen. Psychiatry (1999) 56(1):21-27.
52. TSAI G, YANG P, CHUNG LC et al.: D-Serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry (1998) 44(11):1081-1089.
53. JAVITT DC, SERSHEN H, HACHIM A et al.: Inhibition of striatal dopamine release by glycine and glycyldodecylamide. Brain Res. Bull. (2000) 52(3):213-216.
54. HARSING LG J, GACSALYI I, SZABO G et al.: The glycine transporter-1 inhibitors NFPS and ORG-24461: a pharmacological study. Pharmacol. Biochem. Behav. (2003) 74(4):811-825.
55. SZENASI G, GIGLER G, GACSALYI I et al.: Beneficial and detrimental effects of ORG-24461 and NFPS, two glycine transporter-1 inhibitors, in rats and mice. 6th IBRO World Congress of Neuroscience, (2003), abstract #3189.
56. GOMEZA J, HULSMANN S, OHNO K et al.: Inactivation of the glycine transporter 1 gene discloses vital role of glial glycine uptake in glycinergic inhibition. Neuron (2003) 40(4):785-796.
57. CHEN L, MUHLHAUSER M, YANG CR: Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J. Neurophysiol. (2003) 89(2):691-703.
58. KLITENICK MA, ATKINSON BN, BAKER DA et al.: Development and characterization of GlyT-1-seective glycine reuptake inhibitors. American College of Neuropsychopharmacology 40th Annual Meeting (2001).
59. ALDER CM, GOLDBERG TE, MALHOTRA AK et al.: Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biol. Psychiatry (1998) 43(11):811-816.
60. ATKINSON BN, DEVIVO M, LECHNER SM et al.: Characterization of ALX-5407, a GlyT-1-selective glycine reuptake inhibitor. Soc. Neurosci. (2000) Abstract #69.
61. BROWN A, CARLYLE J, CLARK J et al.: Discovery and SAR of ORG-24598-a selective glycine uptake inhibitor. Bioorg. Med. Chem. Lett. (2001) 11(15):2007-2009.
62. --dependent neurotransmitter transporter activity. Anal. Biochem. (2003) 321(1):31-37.
63. ISAAC M, SLASSI A, DA SIVLA K et al.: 5,5-Diaryl-2-amino-4-pentenoates as novel, potent, and selective glycine transporter Type-2 reuptake inhibitors. Bioorg. Med. Chem. Lett. (2001) 11(11):1371-1373.
64. 3H]-(R)-NPTS, a radioligand for the Type 1 glycine transporter. Bioorg. Med. Chem. Lett. (2003) 13(7):1291-2129.